Trend in antibiotic susceptibility of nosocomial Enterobacteriaceae and usage after introduction of cefepime

Changes in antibiotic usage and susceptibility in nosocomial Enterobacteriaceae and Pseudomonas isolates following the introduction of ertapenem to hospital formulary. Epidemiology and Infection 140(1): 115-125, 2012

A prospective multicenter evaluation of the impact of formulary conversion from ceftazidime to cefepime on the in vitro susceptibility of Pseudomonas aeruginosa The cefepime enterobacteriaceae resistance impact study. Abstracts of the General Meeting of the American Society for Microbiology 101: 21, 2001

Reduced Susceptibility to Cefepime in Clinical Isolates of Enterobacteriaceae Producing OXA-1 Beta-Lactamase. Microbial Drug Resistance 22(2): 141-146, 2015

Evaluation of in vitro activities of cefepime and other beta-lactams against nosocomial Enterobacteriaceae with respect to their beta-lactamase patterns in 8 Russian hospitals. Abstracts of the Interscience Conference on Antimicrobial Agents & Chemotherapy 38: 196, 1998

The impact of a nationwide antibiotic restriction program on antibiotic usage and resistance against nosocomial pathogens in Turkey. International Journal of Medical Sciences 8(4): 339-344, 2011

Antibiotic resistance patterns in nosocomial gram-negative bacterial infections in units with heavy antibiotic usage. Journal of Tropical Pediatrics 50(1): 26-31, 2004

In Vitro Activity of Cefepime/AAI101 and Comparators against Cefepime Non-susceptible Enterobacteriaceae. Pathogens 4(3): 620-625, 2015

Cefepime Therapy for Cefepime-Susceptible Extended-Spectrum β-Lactamase-Producing Enterobacteriaceae Bacteremia. Open Forum Infectious Diseases 3(3): Ofw132-Ofw132, 2016

Improved Accuracy of Cefepime Susceptibility Testing for ESBL-producing Enterobacteriaceae using an On-Demand Digital Dispensing Method. Journal of Clinical Microbiology (): -, 2016

Antimicrobial susceptibility and pharmacodynamic comparison of piperacillin-tazobactam and cefepime against enterobacteriaceae with extended-spectrum beta-lactamase. Abstracts of the Interscience Conference on Antimicrobial Agents & Chemotherapy 41: 197, 2001

Susceptibility of bacterial isolates from nosocomial infections to cefepime and 9 other antibiotics A multicentre study in Poland. Journal of Hospital Infection 40(SUPPL A): P417, Sept, 1998

In vivo activities of simulated human doses of cefepime and cefepime-AAI101 against multidrug-resistant Gram-negative Enterobacteriaceae. Antimicrobial Agents and ChemoTherapy 59(5): 2688-2694, 2016

Cefepime therapy for monomicrobial bacteremia caused by cefepime-susceptible extended-spectrum beta-lactamase-producing Enterobacteriaceae: MIC matters. Clinical Infectious Diseases 56(4): 488-495, 2013

Bacteria susceptibility to cefepime in a hospital before its introduction. Journal of Hospital Infection 40(SUPPL A): P413, Sept, 1998

Nosocomial consequences of antibiotic usage. Scandinavian Journal of Infectious Diseases. Supplementum 49: 182-188, 1986